Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 6NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Breast Neoplasms 30Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 18Lung Neoplasms 14Head and Neck Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Ovarian Neoplasms 7Carcinoma, Ovarian Epithelial 5Adenocarcinoma of Lung 5Inflammatory Breast Neoplasms 4Fallopian Tube Neoplasms 4Esophageal Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Salivary Gland Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms, Male 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrent Uterine Corpus Sarcoma 2Recurrent Squamous Cell Lung Carcinoma 2Carcinoma 2Anatomic Stage I Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1

Interventions

Platinum 4Cisplatin 4Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3regorafenib 2pegfilgrastim 2Radiotherapy, Intensity-Modulated 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Docetaxel 2Bevacizumab 2trifluridine tipiracil drug combination 1pembrolizumab 1merphos 1dehydroftorafur 1X-Rays 1Vinblastine 1Trifluridine 1Taxes 1Specimen Handling 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation 1Nivolumab 1Nephroureterectomy 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Methotrexate 1Irinotecan 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Carcinoma × Docetaxel × Clear all
NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT00887536 2022-04-20

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NSABP Foundation Inc

Phase 3 Completed
1,613 enrolled
Breast

Adenocarcinoma, Breast Diseases, Breast Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡